Abstract: Recent trends in oral contraceptive (OC) were the ultra low-dose estrogen OC regimen, the novel compounds (third-generation progestins, drospirenone, and estradiol valerate), multi-phase OC, and the varied OC regimens including extended and continuous contraceptives. Contraceptive management should take into account women lifestyle and coexisting medical issues, as well as contraceptive efficacy and safety, and noncontraceptive benefits. LO MINASTRIN-FE may reduce those adverse reactions related to estrogen in long-term use, suggesting the improved safety in theory. Safyral contained with DRSP can be used not only for contraception, but also for treatment of premenstrual dysphoric disorder and acne because it can rise the folate level in women. Natazia■ is a new OC with estradiol valerate and dienogest in a unique 4-phasic formulation which could be recommended as an OC for those women with PCOS, insulin resistant or overweight. So far as newer OCs such as 84+7 and 24+4 regimens, their one-year pregnancy rates were significantly lower than this rate of 21+7 regimen. The key challenge now is how to guide the safe use of new OC with new evidence of the evidence-based medicine.

Key words: Contraceptives, oral, Progestins, Cardiovascular diseases, Evidence-based medicine